United Therapeutics Corporation
United Therapeutics Corporation/ US91307C1027 /
UTHR
|
24/05/2024 22:00:00
|
Chg.
-3.6200
|
Volume |
Bid01:53:57 |
Demandez à01:53:57 |
Capitalisation boursière |
Dividende Y. |
Rapport P/E |
|
272.8800USD
|
-1.31%
|
408,164
Chiffrre d'affaires: 57.23 Mio. |
267.8300Bid taille: 100 |
277.3100Ask la taille: 100 |
12.1 Mrd.USD |
- |
12.97 |
Description de l'entreprise
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening cardiovascular and infectious diseases and cancer.
Conseil d'administration & Conseil de surveillance
| PDG |
| Dr. Martine A. Rothblatt |
| Conseil d'administration |
| James C. Edgemond, Michael Benkowitz, Paul A. Mahon |
| Conseil de surveillance |
| Dr. Martine A. Rothblatt, Christopher Causey, Christopher Patusky, Dr. Judy D. Olian, Dr. Katherine J. Klein, Linda Maxwell, M.D., Louis Sullivan, Nilda Mesa, Prof. Raymond Dwek, Ray Kurzweil, Richard Giltner, Tommy G. Thompson |
Données de l'entreprise
| Nom: |
United Therapeutics Corporation |
| Adresse: |
1040 Spring Street,Silver Spring, Maryland 20910, USA |
| Téléphone: |
+1-301-608-9292 |
| Fax: |
+1-301-608-9291 |
| Courriel: |
-
|
| Internet: |
is.gd/1hUSaA |
| Industrie: |
Biotechnology |
| Secteur: |
Biotechnology |
| Sous-secteur: |
Biotechnology |
| Fin de l'exercice financier: |
31/12 |
| Flotte libre: |
61.80% |
| IPO date: |
- |
Relations avec les investisseurs
| Nom: |
- |
| Téléphone IR: |
- |
| IR-Fax: |
- |
| E-mail IR: |
ir@unither.com
|
Principaux actionnaires
| Freefloat |
|
61.80% |
| BlackRock, Inc |
|
9.60% |
| The Vanguard Group |
|
8.90% |
| Renaissance Technologies LLC |
|
8.10% |
| Avoro Capital Advisors LLC |
|
6.40% |
| FMR, LLC |
|
5.20% |
